A nationwide analysis of children hospitalized with laboratory-confirmed influenza has found that treatment with the antiviral drug oseltamivir was associated with a substantially lower risk of intensive care admission and shorter hospital stays. Published in JAMA Pediatrics, the study represents one of the largest real-world evaluations of antiviral effectiveness in pediatric influenza and arrives as the use of these medicines among hospitalized children has declined in recent years.
Researchers analyzed more than 7,000 pediatric influenza hospitalizations recorded by FluSurv-NET, a surveillance system supported by the U.S. Centers for Disease Control and Prevention. The network collects data on laboratory-confirmed influenza hospitalizations across participating states, allowing investigators to examine outcomes over eight influenza seasons from 2014 through 2023. The analysis included children hospitalized in 13 states and compared those who received oseltamivir with those who did not.
Children treated with oseltamivir were 31 percent less likely to be admitted to an intensive care unit than children who did not receive the antiviral. They also had shorter hospital stays, indicating that treatment may influence both the severity of illness and the time required for recovery. Because the study examined routine medical care rather than a controlled clinical trial, the findings describe an association between treatment and improved outcomes, while accounting for several factors that could otherwise distort that association.
Oseltamivir belongs to a class of drugs known as neuraminidase inhibitors. Influenza viruses use the neuraminidase protein on their surface to help newly formed viral particles detach from infected cells and spread through the respiratory tract. By inhibiting this enzyme, oseltamivir can limit the release of virus from infected cells and reduce the progression of infection. The drug does not directly destroy influenza viruses, but it can interfere with viral replication and transmission within the body.
National guidelines recommend antiviral treatment as soon as possible for children hospitalized with suspected or confirmed influenza, regardless of whether treatment begins immediately after symptoms appear. Antivirals are generally most effective when started within the first 48 hours of illness, but hospitalized patients may still benefit when treatment begins later. The new study found that the association with reduced critical-care risk persisted even when oseltamivir was initiated more than two days after the onset of symptoms.
The timing of illness and treatment was central to the study’s design. Earlier observational studies often lacked reliable information about when symptoms began or whether a child had received an antiviral before arriving at the hospital. Those gaps can make treatment appear more or less effective than it truly is, because children treated promptly may differ from untreated children in age, underlying medical conditions, disease severity, access to care or the timing of hospitalization. By incorporating symptom onset and treatment timing into the analysis, the researchers sought to reduce these sources of bias.
The investigators also used advanced statistical methods to account for differences between treated and untreated patients. Such methods cannot fully replicate the conditions of a randomized clinical trial, but they can provide important evidence from large populations receiving care in real hospitals. The breadth of the FluSurv-NET data allowed the researchers to observe outcomes across multiple influenza seasons, circulating viral strains and healthcare settings, strengthening the relevance of the results for pediatric practice.
The findings are particularly significant because influenza can progress rapidly in children, especially those with chronic neurological, respiratory, cardiac or immune-related conditions. Severe infection may trigger viral pneumonia, secondary bacterial infection, respiratory failure or systemic inflammation, all of which can lead to intensive care. Even when an antiviral does not prevent infection, reducing viral activity early in the course of hospitalization could help limit the cascade of complications that places additional strain on the lungs and other organs.
The researchers say the results reinforce existing recommendations rather than establish a new treatment policy. Children hospitalized with suspected or confirmed influenza should be considered for antiviral therapy promptly, including when the exact duration of illness is uncertain or more than 48 hours have passed since symptoms began. The study’s authors emphasize that the decline in antiviral use among hospitalized children is inconsistent with national guidance and may represent a missed opportunity to reduce severe outcomes. For clinicians, the message is that delayed presentation should not automatically exclude a child from treatment; for families, the findings underscore the importance of seeking medical attention when influenza symptoms become severe or rapidly worsen.
Subject of Research: Effectiveness of oseltamivir treatment in children hospitalized with laboratory-confirmed influenza
Article Title: Effectiveness of Oseltamivir in Hospitalized Children with Laboratory-Confirmed Influenza, 2014-2023
Web References: University of Colorado Anschutz; CDC FluSurv-NET
References: JAMA Pediatrics
Keywords: Influenza, influenza viruses, oseltamivir, antiviral treatment, pediatric infectious diseases, children, intensive care, hospitalization, respiratory infection, viral science
